The UK has given emergency authorization for the SARS-CoV-2 vaccine from Pfizer and BioNTech, the Associated Press reports.
The firms announced last month that data from their late-stage clinical trial indicated their mRNA-based candidate vaccine has a 95 percent efficacy.